By Josh White
Date: Wednesday 30 Oct 2024
(Sharecast News) - GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset weaker sales in vaccines. or login to read the full story
The FTSE 100 pharmaceutical giant said overall quarterly revenue totalled £8bn, down 2% at actual exchange rates but up 2% at constant exchange rates.
Email this article to a friend
or share it with one of these popular networks:
You are here: news